NYSE:PKI

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. More Details


Snowflake Analysis

Solid track record with mediocre balance sheet.


Similar Companies

Share Price & News

How has PerkinElmer's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PKI has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

3.5%

PKI

-3.3%

US Life Sciences

-4.1%

US Market


1 Year Return

46.2%

PKI

41.8%

US Life Sciences

12.0%

US Market

Return vs Industry: PKI exceeded the US Life Sciences industry which returned 41.8% over the past year.

Return vs Market: PKI exceeded the US Market which returned 12% over the past year.


Shareholder returns

PKIIndustryMarket
7 Day3.5%-3.3%-4.1%
30 Day2.6%5.1%-0.2%
90 Day8.3%6.2%2.8%
1 Year46.6%46.2%42.1%41.8%14.6%12.0%
3 Year84.1%82.4%91.7%90.5%35.8%26.8%
5 Year152.8%148.0%187.0%183.2%75.2%55.6%

Price Volatility Vs. Market

How volatile is PerkinElmer's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is PerkinElmer undervalued compared to its fair value and its price relative to the market?

34.74x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: PKI ($128.79) is trading above our estimate of fair value ($56.37)

Significantly Below Fair Value: PKI is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: PKI is good value based on its PE Ratio (34.7x) compared to the US Life Sciences industry average (38.8x).

PE vs Market: PKI is poor value based on its PE Ratio (34.7x) compared to the US market (18.1x).


Price to Earnings Growth Ratio

PEG Ratio: PKI's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: PKI is good value based on its PB Ratio (4.5x) compared to the US Life Sciences industry average (6.6x).


Next Steps

Future Growth

How is PerkinElmer forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

-0.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PKI's earnings are forecast to decline over the next 3 years (-0.2% per year).

Earnings vs Market: PKI's earnings are forecast to decline over the next 3 years (-0.2% per year).

High Growth Earnings: PKI's earnings are forecast to decline over the next 3 years.

Revenue vs Market: PKI's revenue (1.6% per year) is forecast to grow slower than the US market (10% per year).

High Growth Revenue: PKI's revenue (1.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PKI's Return on Equity is forecast to be low in 3 years time (16.6%).


Next Steps

Past Performance

How has PerkinElmer performed over the past 5 years?

10.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PKI has high quality earnings.

Growing Profit Margin: PKI's current net profit margins (12.7%) are higher than last year (8.2%).


Past Earnings Growth Analysis

Earnings Trend: PKI's earnings have grown by 10% per year over the past 5 years.

Accelerating Growth: PKI's earnings growth over the past year (76.1%) exceeds its 5-year average (10% per year).

Earnings vs Industry: PKI earnings growth over the past year (76.1%) exceeded the Life Sciences industry 30.4%.


Return on Equity

High ROE: PKI's Return on Equity (12.8%) is considered low.


Next Steps

Financial Health

How is PerkinElmer's financial position?


Financial Position Analysis

Short Term Liabilities: PKI's short term assets ($1.7B) exceed its short term liabilities ($1.2B).

Long Term Liabilities: PKI's short term assets ($1.7B) do not cover its long term liabilities ($2.4B).


Debt to Equity History and Analysis

Debt Level: PKI's debt to equity ratio (56.2%) is considered high.

Reducing Debt: PKI's debt to equity ratio has increased from 48.1% to 56.2% over the past 5 years.

Debt Coverage: PKI's debt is well covered by operating cash flow (34.4%).

Interest Coverage: PKI's interest payments on its debt are well covered by EBIT (12.4x coverage).


Balance Sheet


Next Steps

Dividend

What is PerkinElmer current dividend yield, its reliability and sustainability?

0.22%

Current Dividend Yield


Upcoming Dividend Payment


Dividend Yield vs Market

Notable Dividend: PKI's dividend (0.22%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.69%).

High Dividend: PKI's dividend (0.22%) is low compared to the top 25% of dividend payers in the US market (4.78%).


Stability and Growth of Payments

Stable Dividend: PKI is not paying a notable dividend for the US market, therefore no need to check if payments are stable.

Growing Dividend: PKI is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: PKI is not paying a notable dividend for the US market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PKI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.6yrs

Average management tenure


CEO

Prahlad Singh (55 yo)

0.83

Tenure

US$4,116,556

Compensation

Dr. Prahlad R. Singh, PhD has been the Chief Executive Officer of PerkinElmer, Inc. since December 30, 2019. He serves as Director of PerkinElmer, Inc. since August 21, 2019. He has been President at Perki ...


CEO Compensation Analysis

Compensation vs Market: Prahlad's total compensation ($USD4.12M) is below average for companies of similar size in the US market ($USD11.21M).

Compensation vs Earnings: Prahlad's compensation has increased by more than 20% in the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Prahlad Singh
CEO, President & Director0.83yrUS$4.12m0.034%
$ 4.9m
James Mock
Senior VP & CFO2.42yrsUS$2.11m0.023%
$ 3.4m
Joel Goldberg
Senior VP of Administration12.25yrsUS$2.88m0.063%
$ 9.1m
Robert Friel
0.83yrUS$16.48m0.53%
$ 77.0m
Tajinder Vohra
Senior Vice President of Global Operationsno datano data0.0087%
$ 1.3m
Andrew Okun
VP & Chief Accounting Officer9.5yrsno data0.0092%
$ 1.3m
Bryan Kipp
Vice President of Investor Relationsno datano datano data
Daniel Tereau
Senior Vice President of Strategy & Business Development4.75yrsno data0.0066%
$ 956.2k
David Francisco
CFO of Human Health & Corporate Treasurerno datano datano data
John Healy
VP, Associate General Counsel & Assistant Secretaryno datano datano data
Karen Madden
Vice President of Technology & Innovationno datano datano data

3.6yrs

Average Tenure

52yo

Average Age

Experienced Management: PKI's management team is considered experienced (3.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Prahlad Singh
CEO, President & Director0.83yrUS$4.12m0.034%
$ 4.9m
Alexis Michas
Independent Non-Executive Chairman0.83yrUS$338.48k0.057%
$ 8.2m
Sylvie Gregoire
Independent Director5.58yrsUS$264.98k0.013%
$ 1.9m
Peter Barrett
Independent Director8.58yrsUS$279.98k0.019%
$ 2.7m
Franklin Witney
Independent Director4.25yrsUS$264.98k0.0097%
$ 1.4m
Samuel Chapin
Independent Director4yrsUS$289.98k0.0091%
$ 1.3m
Pascale Witz
Independent Director3yrsUS$264.98k0.0032%
$ 453.6k
Michel Vounatsos
Independent Director0.58yrno data0.0014%
$ 195.8k

3.5yrs

Average Tenure

60.5yo

Average Age

Experienced Board: PKI's board of directors are considered experienced (3.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

PerkinElmer, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: PerkinElmer, Inc.
  • Ticker: PKI
  • Exchange: NYSE
  • Founded: 1937
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$14.401b
  • Shares outstanding: 111.81m
  • Website: https://www.perkinelmer.com

Number of Employees


Location

  • PerkinElmer, Inc.
  • 940 Winter Street
  • Waltham
  • Massachusetts
  • 2451
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PKINYSE (New York Stock Exchange)YesCommon StockUSUSDJan 1968
PKNDB (Deutsche Boerse AG)YesCommon StockDEEURJan 1968
0KHELSE (London Stock Exchange)YesCommon StockGBUSDJan 1968
PKI *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNJan 1968
P1KI34BOVESPA (Bolsa de Valores de Sao Paulo)BDR EACH 2 REPR 1 COMBRBRLJan 2020

Biography

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solution ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/30 03:24
End of Day Share Price2020/10/29 00:00
Earnings2020/10/04
Annual Earnings2019/12/29


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.